Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease

Exclusion criteria

• ✕. Patients with unstable disease (IPF) assessed by investigators during screening had acute exacerbations during screening or within 3 months before randomization;
• ✕. Patients who are likely to require lung transplantation within 6 months or whose expected survival is less than 1 year as assessed by the investigators at the time of screening;
• ✕. During screening, chest HRCT indicated that the range of emphysema exceeded the range of pulmonary fibrosis (based on independent imaging evaluation results);
• ✕. Patients with airway obstruction disease (such as FEV1/FVC after bronchodilator);
• ✕. Diagnosed with IPF
• ✕. Diagnosis of PPF according to the 2022 ATS/ERS/JRS/ALAT guidelines
• ✕. Patients with other types of respiratory diseases that the investigators assessed might affect the study results;
• ✕. Patients who need to receive oxygen therapy for 15 hours or more per day;